Shots:

• Trinity has acquired Metabolomics Diagnostics for an enterprise value of ~$1.3M. The deal includes over 270,000 Trinity Biotech ADS shares, cash & the assumption of liabilities
• The acquisition adds PrePsia test, intended to predict the risk of preeclampsia as early as the 12th week of pregnancy for effective treatment, to Trinity’s portfolio. Its commercialization in the US is anticipated during 2025 through Immco reference laboratory, with in-house manufacturing of its test-reagents
• The test employs mass spectrometry to detect metabolites in blood samples that is combined using ML algorithm with patient-specific clinical data for a preeclampsia risk score. Trinity aims to use this technology to develop additional diagnostic tests in maternal health

Ref: Metabolomics Diagnostics | Image: Metabolomics Diagnostics

Related News:- Telix to Expand its US Operations Through the Acquisition of RLS Radiopharmacies

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com